Eleven Biotherapeutics Inc (NASDAQ:EBIO) shares rose 0% during mid-day trading on Wednesday . The company traded as high as $0.97 and last traded at $0.90. Approximately 1,260,499 shares were traded during mid-day trading, an increase of 17% from the average daily volume of 1,079,899 shares. The stock had previously closed at $0.90.
The stock has a market capitalization of $27.34, a PE ratio of -0.81 and a beta of 3.04.
Several institutional investors have recently bought and sold shares of EBIO. Virtu KCG Holdings LLC bought a new stake in Eleven Biotherapeutics in the 2nd quarter valued at about $175,000. Vanguard Group Inc. lifted its position in Eleven Biotherapeutics by 17.4% in the 2nd quarter. Vanguard Group Inc. now owns 206,450 shares of the biopharmaceutical company’s stock valued at $324,000 after purchasing an additional 30,600 shares during the last quarter. Finally, Municipal Employees Retirement System of Michigan acquired a new position in Eleven Biotherapeutics during the 3rd quarter valued at about $382,000. Institutional investors own 3.84% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Eleven Biotherapeutics (EBIO) Stock Price Up 0%” was published by Ticker Report and is the property of of Ticker Report. If you are accessing this report on another publication, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this report can be read at https://www.tickerreport.com/banking-finance/3126915/eleven-biotherapeutics-ebio-stock-price-up-0.html.
About Eleven Biotherapeutics
Eleven Biotherapeutics, Inc is a preclinical-stage biopharmaceutical company. The Company applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. The Company’s product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema (DME) and uveitis.
Receive News & Ratings for Eleven Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eleven Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.